[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555167":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":28,"responsibleParty":46,"collaborators":20,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":20,"enrollmentInfo":57,"targetDuration":20,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":20,"overallStatus":31,"whyStopped":20,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"University Health Network, Toronto","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"2xHDR Brachytherapy","EXPERIMENTAL","Salvage MR-guided High-Dose-Rate Brachytherapy for Prostate Bed recurrence after Postoperative Radiotherapy.",[13],"Radiation: High Dose Rate Brachytherapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","High Dose Rate Brachytherapy","2 fractions of MRI-guided HDR Brachytherapy (13Gy each) delivered over 14 days (± 7 days).",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":26,"email":27},"Peter Chung, MD","CONTACT","416-946-4501","3374","peter.chung@uhn.ca",[29],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Princess Margaret Cancer Centre","RECRUITING","Toronto","Ontario","M5G1Z5","Canada","CA",{"type":38,"coordinates":39},"Point",[40,41],-79.39864,43.70643,{"lat":41,"lon":40},[44],{"name":45,"role":24,"phone":25,"phoneExt":26,"email":27},"Peter Chung",{"type":47,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100555167","salvage-mr-guided-high-dose-rate-brachytherapy-for-prostate-bed-recurrence-after-radiotherapy-in-the-psma-pet-scan-era-100555167",false,"NCT06508567","Salvage MR-guided High-Dose-Rate Brachytherapy for Prostate Bed Recurrence After Radiotherapy in the PSMA PET Scan Era","SHAPE-PSMA","Inclusion Criteria:\n\n1. Patients who received previous RT to the prostate bed +\u002F- pelvic nodal regions\n2. Prostate-bed recurrence identified by biopsy and\u002For MRI and\u002For PSMA-PET scan\n3. At least two continuous PSA elevations post RT and PSA above 0.2 ng\u002Fdl\n4. With or without ADT PSA doubling time from nadir greater than 6 months\n5. ECOG 0-2\n6. Age greater than 18 years\n\nExclusion Criteria:\n\n1. Radiological (e.g. PSMA PET, CT, MRI or bone scan) evidence of or distant metastases\n2. History of ≥G3 gastrointestinal (GI) and genitourinary (GU) toxicities following RT\n3. Any contraindications to MR and\u002For brachytherapy","MALE","18 Years",{"count":58,"type":59},20,"ESTIMATED","INTERVENTIONAL",[62],"NA","This is an interventional, single-centre, single-arm, non-randomized, prospective, feasibility trial investigating salvage MR-guided High-Dose-Rate brachytherapy for prostate bed recurrence after postoperative radiotherapy.",[65,66],"Prostate Cancer Recurrent","Prostate Cancer","2026-05-21",{"date":69,"type":70},"2026-05-26","ACTUAL",{"date":72,"type":70},"2024-08-08",{"date":74,"type":59},"2031-03-01",{"name":5,"class":6},1]